I don't see any reason for a RS right now ... unless there is big news to go along with it, and a plan. Probably predicated on Zenith advancement and success.

A RS now, without a collateral big move or financing would be disastrous imho. Cut our shares to a fraction, and give some pps space for the shorts and other market games to drive it back down to where it is now. With a fraction of the shares.

Why did Zenith and RVX split anyway? I think there is more value as an issue together. Maybe that is just me seeking shelter for my RVX stock. But with Zenith in promising positions with trials with BP's, and a promising ABL waiting it's next turn, would be a strong package. You can always package them up together, but then you have 2 weaker stocks performing rather than a slightly stronger one, with promising trials occurring and another one on deck (ABL/BoM2).

The real shame and disappointment is the failure of BoM (Stroke / Futility / Bock-on, etc), and then not teaming with BP for the 5 year trial which could be "possibly" approved by now especially with interim anaysis.

The fact that we failed BoM and yet came out of it with BTD (the science is GOOD), is about as glaring of an indictment of mgt as anything.

How does that happen? - where you can't meet primary end points and pass any of your important trials, and yet the FDA and medical academic community is loving on your solutions to "rare air" levels with the BTD??  

Not a fan of RS at all, would rather a recombining of Zenith and RVX at appropriate values, and leveraging the Zenith BP relationships for the future of RVX ... that is unless kings and sheiks start showing up in Calgary with a convoy of camels laden with gold, frankincense, and myrrh.